Updates
Budget, Congressional interactions, Annual Report to the Nation, Leadership
## FY 2018 NCI Budget Overview
(dollars in thousands)

<table>
<thead>
<tr>
<th>Appropriation Increase over FY 2017¹</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>FY 2017 Enacted</td>
<td>$5,389,329</td>
</tr>
<tr>
<td>FY 2018 Enacted</td>
<td>$5,664,800</td>
</tr>
<tr>
<td><strong>Appropriation Increase</strong></td>
<td><strong>$275,471</strong></td>
</tr>
</tbody>
</table>

¹ Does not include $300M 21st Century Cures funding for Cancer Moonshot

<table>
<thead>
<tr>
<th>Estimated Increase, as of 6/22/2018</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Taps, Assessments, Transfers, Salaries &amp; Benefits</td>
<td>$37,900</td>
</tr>
<tr>
<td>Small Business Set Aside</td>
<td>$10,000</td>
</tr>
<tr>
<td>Additional Investments in the RPG Pool</td>
<td>$147,000</td>
</tr>
<tr>
<td>Centers and SPOREs</td>
<td>$20,000</td>
</tr>
<tr>
<td>Targeted Research Opportunities</td>
<td>$60,571</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$275,471</strong></td>
</tr>
</tbody>
</table>
### Targeted Research Opportunities

<table>
<thead>
<tr>
<th>Research Area</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genomic Profiling of Lung Cancer in Never Smokers in General &amp; Special Populations</td>
</tr>
<tr>
<td>The Cancer Imaging Archive</td>
</tr>
<tr>
<td>Data Integration and Analysis for APOLLO</td>
</tr>
<tr>
<td>Glioblastoma Research Pilot Project</td>
</tr>
<tr>
<td>New Onset Diabetes (NOD) Cohort Biorepository</td>
</tr>
<tr>
<td>Cancer Research Education Grants to Promote Diversity (R25’s)</td>
</tr>
</tbody>
</table>

1 This table does not represent the entire population of Targeted Research Opportunities in FY 2018, but rather a select few.
Senate Appropriations Labor-HHS Subcommittee Hearing on FY19 NIH Budget – May 17, 2018

House Appropriations Labor-HHS Subcommittee Hearing on FY19 NIH Budget – April 11, 2018
Senator Jack Reed (D-RI) visit to NCI – May 1, 2018
Edward L. Trimble, MD, MPH

For developing initiatives and collaborating with low- and middle-income countries to support cancer control planning, build capacity and support cancer research and training.
NCI Center for Global Health

Interim leadership

Robert T. Croyle, PhD
Thomas G. Gross, MD, PhD
Lisa Stevens, PhD
Douglas R. Lowy, MD
NCAB Ad Hoc Working Groups

- Global Health
- Data Science Working Group
- SBIR/STTR
- Population Sciences, Epidemiology, and Disparities Working Group (new)
Cancer Moonshot

Sept. 2016

Blue Ribbon Panel Recommendations


21st Century Cures Act
Authorized Funding for Cancer Moonshot

Apr.-Jun. 2017

NCI Teams, Leaders & BSA Develop & Review Scientific Proposals Aligned with BRP Recommendations

Fall 2017

$300M Awarded
FY2018 FOAs Released
Notable NCI Research

NCI Press Release

NCI study finds gut microbiome can control antitumor immune function in liver

Posted: May 24, 2018
Contact: NCI Press Office
240-760-6600

Scientists have found a connection between bacteria in the gut and antitumor immune responses in the liver. Their study, published online May 24 in Science, was led by researchers in the Center for Cancer Research (CCR) at the National Cancer Institute (NCI). It showed that bacteria found in the gut of mice affect the liver’s antitumor immune function. The findings have implications for understanding the mechanisms that lead to liver cancer and for therapeutic approaches to treat them. NCI is part of the National Institutes of Health.

*What we found using different tumor models is that gut bacteria can affect antitumor immunity, which is really exciting because we are beginning to understand that immune checkpoint inhibitors are not the only way to combat cancer.*

3D illustration of gut bacteria.
Credit: Stock

NCI Press Release

NCI study revises molecular classification for most common type of lymphoma

Posted: April 11, 2018
Contact: NCI Press Office
240-760-6600

In a new study, researchers identified genetic subtypes of diffuse large B cell lymphoma (DLBCL) that could help explain why some patients with the disease respond to treatment and others don’t. The study, led by researchers in the Center for Cancer Research (CCR) at the National Cancer Institute (NCI), part of the National Institutes of Health, with additional authors from several institutions around the world, was published online April 11, 2018, in The New England Journal of Medicine.

*These findings are the culmination of two decades of research at NCI and elsewhere, advancing our understanding of the effect of additional genes on the cancer’s behavior.*

*Image of DNA helix*

NCI Press Release

NIH completes in-depth genomic analysis of 33 cancer types

Posted: April 5, 2018
Contact: NCI Press Office
240-760-6600

Researchers funded by the National Institutes of Health have completed a detailed genomic analysis, known as the PanCancer Atlas, on a data set of molecular and clinical information from over 10,000 tumors representing 33 types of cancer.

*"This project is the culmination of more than a decade of groundbreaking work," said NIH Director Francis S. Collins, M.D., Ph.D. "This analysis provides cancer researchers with unprecedented understanding of how, where, and why tumors arise in humans, enabling better-informed clinical trials and future treatments for patients.*

*Image of cancer cells in purple surrounded by healthy cells in pink*
Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer
NCI at ASCO

MATCH

NF1
**Trial Assigning Individualized Options for Treatment (TAILORx)**

“**I think it’s been well spent**”

- Dinah S. Singer, Ph.D.
Key Focus Areas

**BASIC SCIENCE**
Reaffirm our commitment to basic science to drive novel approaches and technologies

**WORKFORCE DEVELOPMENT**
Support the cancer research enterprise by focusing on the workforce of cancer investigators

**BIG DATA**
Increase data aggregation and interpretation to speed our work across the cancer enterprise

**CLINICAL TRIALS**
Fully realize the power of clinical trials through innovative design, administration, and analyses
Key Focus Areas

**BASIC SCIENCE**
Reaffirm our commitment to basic science to drive novel approaches and technologies

**WORKFORCE DEVELOPMENT**
Support the cancer research enterprise by focusing on the workforce of cancer investigators

**BIG DATA**
Increase data aggregation and interpretation to speed our work across the cancer enterprise

**CLINICAL TRIALS**
Fully realize the power of clinical trials through innovative design, administration, and analyses
Basic Science:
Frederick National Lab Updates

RAS

CryoEM

Frederick Cell Facility
Key Focus Areas

**BASIC SCIENCE**
Reaffirm our commitment to basic science to drive novel approaches and technologies

**WORKFORCE DEVELOPMENT**
Support the cancer research enterprise by focusing on the workforce of cancer investigators

**BIG DATA**
Increase data aggregation and interpretation to speed our work across the cancer enterprise

**CLINICAL TRIALS**
Fully realize the power of clinical trials through innovative design, administration, and analyses
Workforce Training & Development

- Ensure diversity and representation
- Encourage training of the right skills (Ks and Rs)
- Set aside R01 funding for early-stage investigators (ESIs)
- Method to Extend Research in Time (MERIT) – R37
NCI recognizes that Early Stage Investigators (ESI) face challenges. In addition to increased ESI payline, NCI is announcing its new use of the MERIT Award in 2018. The award gives eligible investigators applying for first R01 the opportunity to obtain up to seven years of grant funding (5+2). This will provide critical time for ESIs to launch their careers and become more established before attempting renewal.
NIH Next Generation Researchers Initiative

NIH has launched the Next Generation Researchers Initiative to address longstanding challenges faced by researchers trying to embark upon and sustain independent research careers, and to take steps to promote the growth, vitality and diversity of the biomedical research workforce.

Policy
On August 31, 2017, NIH announced policy details in the NIH Guide Notice: "Policy: Supporting the Next Generation Researchers Initiative (NOT-GD-17-101)". The policy amends the definitions of, and policies supporting, early stage investigators (ESIs). In addition, it creates a new policy for early established investigators (E01s), previously referred to as mid-career investigators, and describes how NIH will monitor the implementation of the policy to determine the impact on ESIs and E01 diversity in the NIH portfolio. Further information can be found on the policy page. Learn more about NIH policies to support ESIs and E01s.

Background
NIH and its stakeholder community have for many years been concerned about the long-term stability of the biomedical research enterprise. Too many researchers vying for limited resources has led to a hypercompetitive environment. Many highly meritorious applications go unfunded. This has too often resulted in misaligned incentives and unintended consequences for talented researchers at all career stages who are trying to succeed and stay in science. The current environment is particularly challenging for many new- and mid-career investigators.

Over the last several years, NIH has taken numerous steps to balance, strengthen, and stabilize the biomedical research enterprise.
Key Focus Areas

**BASIC SCIENCE**
Reaffirm our commitment to basic science to drive novel approaches and technologies

**WORKFORCE DEVELOPMENT**
Support the cancer research enterprise by focusing on the workforce of cancer investigators

**BIG DATA**
Increase data aggregation and interpretation to speed our work across the cancer enterprise

**CLINICAL TRIALS**
Fully realize the power of clinical trials through innovative design, administration, and analyses
Big Data: Data Infrastructure Investments

- Cancer Cloud Resources
- Data Commons Framework Services
- New reporting tools for better insight into active clinical trials
- Recommitment to DOE collaboration*
- Prototype CRDC nodes for imaging and proteomics*
- Collaborations that enable integration of EHR and insurance claims data with SEER*

*Supported by funds authorized by the 21st Century CURES Act.
Big Data: Expanded SEER Program Contract Awards
Key Focus Areas

**BASIC SCIENCE**
Reaffirm our commitment to basic science to drive novel approaches and technologies

**WORKFORCE DEVELOPMENT**
Support the cancer research enterprise by focusing on the workforce of cancer investigators

**BIG DATA**
Increase data aggregation and interpretation to speed our work across the cancer enterprise

**CLINICAL TRIALS**
Fully realize the power of clinical trials through innovative design, administration, and analyses
Clinical Trials

MATCH

LungMAP

ALCHEMIST

NCI-MPACT

Pediatric MATCH
NAVIGATE
NCI and VA Interagency Group to Accelerate Trials Enrollment

NAVIGATE will make it easier for veterans to access state-of-the-art treatments via clinical trials by bringing the trials to them, rather than seeking treatment outside of the Veterans Health Administration.